Solid Biosciences (SLDB) Company Overview

Solid Biosciences rises as the FDA clears SGT-212, a gene therapy candidate, for clinical studies for the treatment of Friedreich's ataxia.

- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich's ataxia -

Wedbush initiated coverage on Solid Biosciences, Inc. SLDB, a gene therapy company focused on treating Duchenne muscular dystrophy (DMD).

– Patients dosed in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne); Dosing was well tolerated in all patients with initial data expected Q4 2024 –

Solid Biosciences (NASDAQ: SLDB) recently released their first quarter 2024 financial results, reporting an earnings per share of -64 cents.

Solid Biosciences is concentrating on advancing gene therapy for neuromuscular and cardiac disorders, with their primary focus being on a drug therapy for Duchenne muscular dystrophy (DMD) that is scheduled for testing in the second quarter of 2024. The company has recently received added funding from a private investment in public equity (PIPE), which has enhanced its risk-reward balance.

Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.

British billionaire Joe Lewis, who owns the Tottenham Hotspur football club, has pleaded guilty to insider trading charges in New York, after prosecutors had charged him with sharing secret stock tips with his pilots, girlfriends and assistants for years.

Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.